Staging and kinetics of multiple myeloma.

[1]  B. Durie,et al.  Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Bataille,et al.  Prognostic factors and staging in multiple myeloma: a reappraisal. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Grogan,et al.  Immunotopographic assessment of lymphoid and plasma cell malignancies in the bone marrow. , 1985, Human pathology.

[4]  T. Grogan,et al.  CALLA-positive myeloma: an aggressive subtype with poor survival. , 1985, Blood.

[5]  F. Mandelli,et al.  Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy , 1984, British journal of haematology.

[6]  B. Durie.  IS MYELOMA REALLY A MONOCLONAL DISEASE? , 1984, British journal of haematology.

[7]  H. Garewal,et al.  Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Bataille,et al.  Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. , 1983, British journal of haematology.

[9]  B. Barlogie,et al.  Marrow cytometry and prognosis in myeloma. , 1983, The Journal of clinical investigation.

[10]  R. Kyle,et al.  Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. , 1983, Blood.

[11]  S. Salmon,et al.  Human myeloma in vitro colony growth: interrelationships between drug sensitivity, cell kinetics, and patient survival duration. , 1983, Blood.

[12]  M. Boccadoro,et al.  Kinetics of circulating B lymphocytes in human myeloma. , 1983, Blood.

[13]  M. Björkholm,et al.  T cells in monoclonal gammopathies. , 2009, Scandinavian journal of haematology.

[14]  R. Bataille,et al.  Bone scintigraphy in plasma-cell myeloma. A prospective study of 70 patients. , 1982, Radiology.

[15]  R. Kyle,et al.  "Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients. , 1982, The New England journal of medicine.

[16]  H. Ludwig,et al.  Radiography and bone scintigraphy in multiple myeloma: a comparative analysis. , 1982, The British journal of radiology.

[17]  R. Makuch,et al.  Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: clinical implications. , 1982, Blood.

[18]  Kyle Ra.  Monoclonal gammopathy of undetermined significance (MGUS): a review. , 1982, Clinics in haematology.

[19]  Bergsagel De.  Plasma cell neoplasms and acute leukaemia. , 1982 .

[20]  B. Barlogie,et al.  Quantitative cytology in myeloma research. , 1982, Clinics in haematology.

[21]  B. Barlogie,et al.  Ploidy and proliferative characteristics in monoclonal gammopathies. , 1982, Blood.

[22]  F. Cozzolino,et al.  [Cytochemical studies of bone marrow plasma cells in monoclonal gammapathies (author's transl)]. , 1982, Nouvelle revue francaise d'hematologie.

[23]  G. Holm,et al.  Monoclonal blood lymphocytes in benign monoclonal gammopathy and multiple myeloma in relation to clinical stage. , 2009, Scandinavian journal of haematology.

[24]  H. Sather,et al.  Immunologic evaluation in the prognosis of acute lymphoblastic leukemia. A report from Childrens Cancer Study Group. , 1981, Blood.

[25]  J. Gutterman,et al.  Chemoimmunotherapy for multiple myeloma , 1981, Cancer.

[26]  F. Singer,et al.  Radiographic and radionuclide imaging in multiple myeloma: the role of gallium scintigraphy: concise communication. , 1981, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  B. Barlogie,et al.  The growth fraction of human myeloma cells. , 1981, Blood.

[28]  H. Wahner,et al.  Scintigraphic evaluation of the skeleton in multiple myeloma. , 1980, Mayo Clinic proceedings.

[29]  G. Holm,et al.  Monoclonal B Lymphocytes in Multiple Myeloma , 1980, Scandinavian journal of immunology.

[30]  W. Pruzanski,et al.  Suppression of polyclonal immunoglobulins in multiple myeloma: relationship to the staging and other manifestations at diagnosis. , 1980, Clinical immunology and immunopathology.

[31]  E. Cooper,et al.  Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring. , 1980, British Journal of Cancer.

[32]  R. Alexanian.  Localized and indolent myeloma. , 1980, Blood.

[33]  S. Salmon,et al.  REAPPRAISAL OF PLATEAU PHASE IN MYELOMA , 1980, The Lancet.

[34]  R. Kyle,et al.  Smoldering multiple myeloma. , 1980, The New England journal of medicine.

[35]  G. Merlini,et al.  A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients. , 1980, Blood.

[36]  R. Bataille,et al.  Myeloma bone marrow acid phosphatase staining: a correlative study of 38 patients , 1980 .

[37]  J. Woolfenden,et al.  Comparison of bone scintigraphy and radiography in multiple myeloma. , 1980, Radiology.

[38]  B. Barlogie,et al.  Cellular DNA content as a marker of human multiple myeloma. , 1980, Blood.

[39]  S. Salmon,et al.  Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. , 1980, Blood.

[40]  F. Kiil,et al.  Influence of plasma potassium concentration on the capacity for sodium reabsorption in the diluting segment of the kidney. , 1980, Scandinavian journal of clinical and laboratory investigation.

[41]  A. Miller,et al.  The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. , 1979, The New England journal of medicine.

[42]  T. Pajak,et al.  Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. , 1979, Blood.

[43]  J. Malpas,et al.  Clinical Staging in Multiple Myeloma , 1979, British journal of haematology.

[44]  Richard Glover,et al.  Stokes Recognized , 1999, Environmental Health Perspectives.

[45]  D. Hollard,et al.  beta-Glucuronidases plasmocytaires dans les dysglobulinémies. Intérêt diagnostique de leur mise en évidence. , 1979 .

[46]  H. Silberman,et al.  Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma. , 1979, Blood.

[47]  J. Cassuto,et al.  Plasma cell acid phosphatase, a discriminative test for benign and malignant monoclonal gammopathies. , 1977, Biomedicine / [publiee pour l'A.A.I.C.I.G.].

[48]  B. Drewinko,et al.  Growth kinetics of plasma cell myeloma. , 1977, Journal of the National Cancer Institute.

[49]  S. Wampler,et al.  Multiple myeloma: quantitative staging and assessment of response with a programmable pocket calculator. , 1977, Blood.

[50]  M. Boccadoro,et al.  Early recruitment in the human myeloma cell population after cytostatic treatment. , 1976, Haematologica.

[51]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.

[52]  S. Salmon,et al.  Expansion of the growth fraction in multiple myeloma with alkylating agents. , 1975, Blood.

[53]  S. Salmon,et al.  Kinetics of tumor growth and regression in IgG multiple myeloma. , 1972, The Journal of clinical investigation.

[54]  S. Salmon,et al.  Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. , 1970, The Journal of clinical investigation.

[55]  J. Fahey,et al.  THE FORMATION OF MYELOMA PROTEIN BY A MOUSE PLASMA CELL TUMOR , 1958, The Journal of experimental medicine.